Vanguard Global Advisers
AVBP icon

Vanguard Global Advisers’s ArriVent BioPharma AVBP Stock Holding History

Vanguard Global Advisers’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Buy
11,704
+941
+9% +$27.8K ﹤0.01% 2192
2026
Q1 		$248K Buy
+10,763
New +$243K ﹤0.01% 2332

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's AVBP Position: Q2 2026 in Review

Vanguard Global Advisers increased its ArriVent BioPharma (AVBP) stake by 8.7% in Q2 2026, buying an estimated $27.8K and bringing the position to 11,704 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

Vanguard Global Advisers first reported a position in AVBP in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Vanguard Global Advisers held 11,704 shares of ArriVent BioPharma worth $407K as of Q2 2026.
  • Vanguard Global Advisers bought 941 ArriVent BioPharma shares in Q2 2026, an estimated $27.8K.
  • ArriVent BioPharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2192 holding.
  • Vanguard Global Advisers first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.